# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k063206   
B. Purpose for Submission: New device   
C. Measurand: Homocysteine   
D. Type of Test: Quantitative, competitive immunoassay using particle-enhanced nephelometry   
E. Applicant: Dade Behring, Inc.

# F. Proprietary and Established Names:

Dimension Vista® HCYS Flex® reagent cartridge, Dimension Vista® Protein 1 Calibrator, Dimension Vista® Protein 1 Control L, M, H.

G. Regulatory Information:   

<table><tr><td rowspan=1 colspan=4>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=2 colspan=4>UrinaryHomocysteine(Nonquantitative)</td><td rowspan=3 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1377.</td><td rowspan=3 colspan=1>75 ClinicalChemistry (CH)</td></tr><tr><td rowspan=2 colspan=1>Urinaryhomocysteine(nonquantitative)test system.</td></tr><tr><td rowspan=1 colspan=4>Test System (LPS)</td></tr><tr><td rowspan=1 colspan=4>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=4>Calibrators, Multi-</td><td rowspan=2 colspan=1>Class II</td><td rowspan=2 colspan=1>21 CFR 862.1150,Calibrator</td><td rowspan=2 colspan=1>75 ClinicalChemistry (CH)</td></tr><tr><td rowspan=1 colspan=4>Analyte Mixture(JIX)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=4>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=4>Multi-Analytecontrols, All kinds</td><td rowspan=2 colspan=1>Class I</td><td rowspan=2 colspan=1>21 CFR 862.1660,Quality ControlMaterial (assayedand unassayed)</td><td rowspan=2 colspan=1>75 ClinicalChemistry (CH)</td></tr><tr><td rowspan=1 colspan=2>(Assayed and</td><td rowspan=1 colspan=2>(Assayed andUnassayed) (JJY)</td><td rowspan=1 colspan=1>(Assayed and</td></tr></table>

# H. Intended Use:

1. Intended use(s): See Indications for use below.

2. Indication(s) for use:

Dimension Vista® HCYS Flex® reagent cartridge: The HCYS method is an in vitro diagnostic test for the quantitative determination of total homocysteine in human serum, heparinized and EDTA plasma. Measurements of homocysteine aid in the diagnosis and treatment of patients suspected of having hyperhomocysteinemia and homocystinuria.

Dimension Vista® Protein 1 Calibrator: PROT1 CAL is an in vitro diagnostic product for the calibration of the C3 Complement (C3), C4 Complement (C4), Homocysteine (HCYS), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM) and prealbumin/Transthyretin (PREALB) methods on the Dimension Vista® System.

Dimension Vista® Protein 1 Control L, M, H: PROT1 CON L, M, H are assayed intralaboratory quality controls for assessment of precision and analytical bias in the determination of C3 Complement (C3), C4 Complement (C4), Homocysteine (HCYS), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M (IGM) and prealbumin/Transthyretin (PREALB) methods on the Dimension Vista® System.

3. Special conditions for use statement(s): Prescription use only

4. Special instrument requirements: For use on the Dimension Vista® System only.

# I. Device Description:

1. Dimension Vista® HCYS Flex® reagent cartridge contains 12 wells with different kinds of reagents: Wells 1-4 contain diluent, wells 5-6 contain HCYS Reduction reagents (0.35 $\mathrm { g / L }$ Dithiothreitol and $0 . 0 0 7 5 { \mathrm { g / L } }$ Adenosine), wells 7-8 contain HCYS supplement reagent 1 $\mathrm { \hbar } 0 . 0 2 \mathrm { g / L }$ conjugate of S-Adenosyl-Cysteine/Porcine Thyreoglobulin), wells 9- 10 contain HCYS supplement reagent 2 (8,100 Units/L recombinant S-Adenosyl-LHomocysteine hydrolase), wells 11-12 contain $1 . 2 5 \ \mathrm { g / L }$ of polystyrene particles and $ { 0 . 0 3 8 ~ \mathrm { g / L } }$ mouse monoclonal antibodies to S-Adenosyl-Homocysteine).

2. Dimension Vista® Protein 1 Calibrator is a multi-analyte, liquid, human serum based product containing C3, C4, Homocysteine, IGA, IGG, IGM, and prealbumin/Transthyretin (PREALB). Each carton contains 6 vials with 6 different concentrations of analytes, each vial contains $2 . 0 \mathrm { m L }$ of ready to use material.

3. Dimension Vista® Protein 1 Control L(low), M(medium), H(high) are multi-analyte, liquid, human serum based products containing C3, C4, Homocysteine, IGA, IGG, IGM, and prealbumin/Transthyretin (PREALB). Each carton contains 6 vials with $2 . 0 \mathrm { m L }$ of ready to use material per vial.

All human source materials were tested and found to be negative for syphilis, HIV 1/2, HBsAg, and HCV.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dade Behring N Latex HCY Dade Behring N Protein Standard SL Dade Behring N/T Protein Control SL

2. Predicate 510(k) number(s): k052788, k012470, k01268

3. Comparison with predicate:

Dimension Vista® HCYS Flex® reagent cartridge:   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative in vitrodiagnostic determination oftotal homocysteine fordiagnosis and treatment ofhyperhomocysteinemia andhomocystinuria.</td><td rowspan=1 colspan=1>Quantitative in vitrodiagnostic determination oftotal homocysteine fordiagnosis and treatment ofhyperhomocysteinemia andhomocystinuria.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Particle Enhancednephelometry</td><td rowspan=1 colspan=1>Particle Enhancednephelometry</td></tr><tr><td rowspan=1 colspan=1>Standardization</td><td rowspan=1 colspan=1>Traceable to purified S-adenosyl-homocysteine.</td><td rowspan=1 colspan=1>Traceable to purified S-adenosyl-homocysteine.</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Mouse monoclonal</td><td rowspan=1 colspan=1>Mouse monoclonal</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Serum or Plasma</td><td rowspan=1 colspan=1>Serum or Plasma</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Dade Behring DimensionVista System</td><td rowspan=1 colspan=1>Dade Behring BN II and BNProSpec System</td></tr><tr><td rowspan=1 colspan=1>Detection Limits</td><td rowspan=1 colspan=1>0.2 μmol/L</td><td rowspan=1 colspan=1>2.0 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Reportable range</td><td rowspan=1 colspan=1>2.0 to 57 µmol/L</td><td rowspan=1 colspan=1>2.0 to 64 µmol/L</td></tr><tr><td rowspan=1 colspan=1>Normal range</td><td rowspan=1 colspan=1>5.0 - 15.0 μmol/LFrom scientific literatures</td><td rowspan=1 colspan=1>3.2 - 10.7 µmol/LFrom scientific literatures</td></tr></table>

Dimension Vista® Protein 1 Calibrator:   

<table><tr><td rowspan=1 colspan=3>Similarities and differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid, human serum</td><td rowspan=1 colspan=1>Liquid, human serum</td></tr><tr><td rowspan=1 colspan=1>Constituents</td><td rowspan=1 colspan=1>C3, C4, homocysteine,IGA, IGG, IGM andprealbumin/Transthyretin</td><td rowspan=1 colspan=1>IgG, IgG1, IgG2, IgG3, IgG4,IgA, homocysteine, IgE,C3,C4, transferrin, albumin,α1-antitrypsin, α2-macroglobulin, haptoglobin,α1-acid glycoprotein,prealbumin, hemopexin,ceruloplasmin, retinal bindingprotein, Ig light-chain kappa,Ig light-chain lambda, solubletransferring receptor, ferritin,β2-microglobulin, totalprotein</td></tr><tr><td rowspan=1 colspan=1>Traceable</td><td rowspan=1 colspan=1>Traceable to purified S-adenosyl-homocysteine.</td><td rowspan=1 colspan=1>Traceable to purified S-adenosyl-homocysteine.</td></tr></table>

Dimension Vista® Protein 1 Control L, M, H:   

<table><tr><td rowspan=1 colspan=3>Similarities and differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid, human serum</td><td rowspan=1 colspan=1>Liquid, human serum</td></tr><tr><td rowspan=1 colspan=1>Constituents</td><td rowspan=1 colspan=1>C3, C4, homocysteine,IGA, IGG, IGM andprealbumin/Transthyretin</td><td rowspan=1 colspan=1>IgG, IgG1, IgG2, IgG3,IgG4, IgA, homocysteine,IgE, C3,C4, transferrin,albumin, α1-antitrypsin, α2-macroglobulin, haptoglobin,α1-acid glycoprotein,prealbumin, hemopexin,ceruloplasmin, retinalbinding protein, Ig light-chain kappa, Ig light-chainlambda, soluble transferringreceptor, ferritin, β2-microglobulin, total protein</td></tr><tr><td rowspan=1 colspan=1>Traceable</td><td rowspan=1 colspan=1>Purified S-adenosyl-homocysteine.</td><td rowspan=1 colspan=1>Purified S-adenosyl-homocysteine.</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable):   

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>CSLI Guideline, EP5-A2 Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline Second edition</td></tr><tr><td>CSLI Guideline, EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline</td></tr><tr><td>Second edition CSLI Guideline, EP9-A2 Method Comparison and Bias Estimation Using Patient Samples;</td></tr></table>

# L. Test Principle:

Bound homocysteine in the sample is reduced to free homocysteine by the action of dithiothreitol, and converted enzymatically to S-adenosyl-homocysteine (SAH) in the next step. Conjugated S-adenosyl-cysteine (SAC) added at the onset of the reaction competes with the SAH in the sample for bonding by anti-SAH antibodies bound to polystyrene particles. In the presence of SAH there is either no aggregation or a weaker aggregation of the polystyrene particles. In the absence of SAH in the sample an aggregation of the polystyrene particles by conjugated SAC occurs. The higher the SAH content of the reaction mixture, the smaller the scattered light signal. The result is evaluated by comparison with a standard of known concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision was evaluated with quality control materials (L, M, H), a plasma pool and two serum pool on the Dimension Vista System following CLSI EP5-A2 guideline. Samples were analyzed in duplicate, twice a day, for 20 days. The repeatability and within-lab SD and $\%$ CV were calculated by the analysis of variance method. The data are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Material</td><td rowspan=1 colspan=1>Meanμmol/L</td><td rowspan=1 colspan=1>RepeatabilitySD (%CV)</td><td rowspan=1 colspan=1>Within-LabSD (%CV)</td></tr><tr><td rowspan=1 colspan=1>PROT1 CON L</td><td rowspan=1 colspan=1>8.90</td><td rowspan=1 colspan=1>0.297 (3.3)</td><td rowspan=1 colspan=1>0.618 (7.0)</td></tr><tr><td rowspan=1 colspan=1>PROT1CON M</td><td rowspan=1 colspan=1>14.06</td><td rowspan=1 colspan=1>0.442 (3.2)</td><td rowspan=1 colspan=1>1.014 (7.2)</td></tr><tr><td rowspan=1 colspan=1>PROT1 CON H</td><td rowspan=1 colspan=1>28.63</td><td rowspan=1 colspan=1>0.829 (2.9)</td><td rowspan=1 colspan=1>1.833 (6.4)</td></tr><tr><td rowspan=1 colspan=1>Serum pool</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>0.332 (3.0)</td><td rowspan=1 colspan=1>0.749 (6.7)</td></tr><tr><td rowspan=1 colspan=1>Serum pool</td><td rowspan=1 colspan=1>53.24</td><td rowspan=1 colspan=1>1.034 (1.9)</td><td rowspan=1 colspan=1>1.447 (6.7)</td></tr><tr><td rowspan=1 colspan=1>Plasma pool</td><td rowspan=1 colspan=1>5.42</td><td rowspan=1 colspan=1>0.104 (1.9)</td><td rowspan=1 colspan=1>0.445 (8.2)</td></tr></table>

# b. Linearity/assay reportable range:

Linearity across the assay range was determined by testing a calibrator and a high patient serum with a high concentration of homocysteine. The samples were serially diluted with system diluent and each dilution was tested with replicates of three. Data were analyzed using linear regression analysis. The acceptance criteria of slope between 0.9 and 1.1 and correlation coefficient $\geq 0 . 9 5$ was met for the study.

The reportable range for the assay is 2 – 57 μmol/L.

The sponsor recommends a dilution of 1:10 when patient result falls outside the upper measuring range of ${ 5 7 } \mathrm { { \mu m o l / L } }$ . A dilution study for homocysteine was performed on 8 different patient serum spiked with homocysteine on the Dimension vista system. Each sample was then diluted with system diluent at 1:10 dilution by the analyzer or manually. Each diluted sample was run in replicates of 5. The $\%$ recovery of the Dimension vista system for homocysteine assay ranged from $91 \%$ to $1 0 0 . 7 \%$ with a mean $\%$ recovery of $94 \%$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability and value assignments:

The PROT1 calibrators and PROT1 controls are calibrated against an internal master calibrator, which is calibrated against a commercially available reference preparation. Specifically, homocysteine is calibrated against a commercially available preparation of purified S-adenosyl-homocysteine. The value assignment process for the standard and control are by an internal protocol using two different instruments and by performing multiple determinations using the Dimension Vista Systems and the Dimension HCYS Reagent. The PROT1 calibrators and PROT1 controls are traceable to purified S-adenosyl-homocysteine.

Stability:

To support a 24 month shelf-life for unopened Dimension Vista HCYS flex reagent, PROT1 calibrators and PROT1 controls store at $2 { - } 8 ^ { \circ } \mathrm { C }$ , testing was done on day 0 and after 12, 18, and 24 months. The acceptance criteria are: results obtained must be within a range of $8 5 \%$ to $1 1 5 \%$ of the control assigned value.

To support an open-vial stability at $2 { - } 8 ^ { \circ } \mathrm { C }$ for the Dimension Vista HCYS flex reagent, PROT1 calibrators and PROT1 controls, vials are stored on board the instrument and contents are tested in duplicates on day 0, 4, 7, 9, 11, 14. The acceptance criteria are: results obtained must not deviate more than $\pm 1 0 \%$ compared to day 0 results. The sponsor claims the on-board stability of 9 days for the calibrators and controls once the vial is opened. The open well stability of the HCYS Flex reagent cartridge is 21 days for wells 1-12. Sealed wells on the instrument are stable for 30 days.

# d. Detection limit:

The analytical sensitivity is defined as the minimal detectable level of analyte, which can be distinguished from zero. The value was calculated as the mean value of twenty replicates of system diluent plus two standard deviations. The sponsor claims the analytical sensitivity to be $0 . 2 \mu \mathrm { m o l / L }$ .

The reportable range for the assay is 2 – 57 μmol/L.

# e. Analytical specificity:

The HCYS method was evaluated for interference according to CLSI/NCCLS EP7-A2. Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding $10 \%$ is considered interference.

<table><tr><td>Substance tested</td><td>Substance Concentration</td><td>S. I. Units</td><td>Homocysteine Concentration μmol/L</td><td>Bias* %</td></tr><tr><td>Hemoglobin (hemolysate)</td><td>1000 mg/dL</td><td>0.62 mmol/L</td><td>13.22</td><td>±0</td></tr><tr><td>Bilirubin (unconjugated)</td><td>60 mg/dL</td><td>1026 μmol/L</td><td>12.54</td><td>±0</td></tr><tr><td>Bilirubin (conjugated)</td><td>60 mg/dL</td><td>1026 μmol/L</td><td>13.28</td><td>+6</td></tr><tr><td>Lipemia (Triglycerides)</td><td>510 mg/dL</td><td>5.7 mmol/L</td><td>11.83</td><td>-7</td></tr></table>

# \* Analyte results should not be corrected based on this bias.

# Non Interfering Substances

The following substances do not interfere with the HCYS method when present in serum and plasma at the concentrations indicated. Inaccuracies (biases) due to these substances are less than $10 \%$ at homocysteine concentrations of $3 . 5 0 \ \mu \mathrm { m o l / L }$ to $2 8 . 8 8 \ \mu \mathrm { m o l / L }$ .

# Substance

# Test Concentration

Acetaminophen   
Adenosine   
Amikacin   
Aminophyllin   
Ammonium heparin

$1 3 2 8 ~ \mathrm { \textmu m o l / L }$   
0.01 mmol/dL   
256 µmol/L   
0.0095 mmol/dL   
3000 U/L

Ampicillin   
Ascorbic acid   
Caffeine   
Carbamazepine   
Chloramphenicol   
Chlordiazepoxide   
Chlorpromazine   
Cholesterol   
Cimetidine   
Creatinine   
Dextran 40   
Diazepam   
Digoxin   
Erythromycin   
Ethanol   
Ethosuximide   
Furosemide   
Gentamicin   
Ibuprofen   
Immunoglobulin G (IgG)   
L-Cystathion   
L-Cysteine   
L-Glutathione   
L-Homocysteine-thiolactone   
Lidocaine   
Lithium chloride   
Lithium heparin   
L-Methionine   
Nicotine   
Penicillin G   
Pentobarbital   
Phenobarbital   
Phenytoin   
Primidone   
Propoxyphene   
Protein Albumin   
Protein Total   
Rheumatoid Factor   
S-Adenosyl-L-methionine   
Salicylic acid   
Sodium heparin   
Urea   
Uric acid   
Valproic acid

5.3 mg/dL 152 µmol/L   
5 mg/dL 227 µmol/L   
6 mg/dL 308 µmol/L   
3 mg/dL 127 µmol/L   
5 mg/dL 155 µmol/L   
1 mg/dL 33.3 µmol/L   
0.2 mg/dL 6.27 µmol/L   
500 mg/dL 12.9 mmol/L   
2 mg/dL 79.2 µmol/L   
30 mg/dL 2652 µmol/L   
6000 mg/dL 1500 µmol/L   
0.5 mg/dL 17.6 µmol/L   
5 ng/mL 6.15 nmol/L   
6 mg/dL 81.6 µmol/L   
400 mg/dL 86.8 mmol/L   
25 mg/dL 1770 µmol/L   
6 mg/dL 181 µmol/L   
12 mg/dL 251 µmol/L   
50 mg/dL 2425 µmol/L   
5 g/dL 50 g/L   
2.23 mg/dL 0.25 mmol/dL   
30 mg/dL 0.01 mmol/dL   
2.142 mg/dL 3.5 mmol/dL   
0.0775 mg/dL 0.5 µmol/dL   
1.2 mg/dL 51.2 µmol/L   
2.3 mg/dL 3.2 mmol/L   
3 U/mL 3000 U/L   
6 mg/dL 0.04 mmol/dL   
0.1 mg/dL 6.2 µmol/L   
25 U/mL 25000 U/L   
8 mg/dL 354 µmol/L   
10 mg/dL 431 µmol/L   
5 mg/dL 198 µmol/L   
4 mg/dL 183 µmol/L   
0.2 mg/dL 4.91 µmol/L   
0.6 g/dL 6 g/L   
12 g/dL 120g/L   
500 U/mL 500 U/mL   
20 mg/dL 0.05 mmol/dL   
60 mg/dL 4.34 mmol/L   
3 U/mL 3000 U/L   
500 mg/dL 83.3 mmol/L   
20 mg/dL 1190 µmol/L   
50 mg/dL 3467 µmol/L

A serum sample above the assay range was analyzed on both the BN ProSpec System and the Dimension Vista System to show that the HCYS assay has no hook effect with concentration up to $1 9 9 . 3 \ \mu \mathrm { m o l / L }$ .

As limitations, the applicant stated the followings in the package insert:

1. Specimens from patients who are on drug therapy involving S-adenosymethionine may show falsely elevated levels of homocysteine. Certain drugs, such as antiepileptic, antifolates, nitrous oxide anesthesia and antagonists of vitamin B6 are known to elevate the homocysteine concentration in human blood.

2. Patient samples may contain heterophilic antibodies that could react in immunoassays to give falsely elevated or depressed results. This assay has been designed to minimize interference from heterophilic antibodies. Nevertheless, complete elimination of this interference from all patient specimens cannot be guaranteed.

f. Assay cut-off: None

2. Comparison studies:

a. Method comparison with predicate device:

A method comparison study was performed on 215 matched samples of serum, EDTA plasma, and heparized plasma based on the CLSI EP9-A2 guideline on the Dimension Vista system and the BN ProSpec system. Samples concentration range from 3.43 to $5 6 . 5 2 \mu \mathrm { m o l / L }$ . The method used to fit the linear regression line was Passing Bablok. Regression analysis of these results yielded the following equation: $\mathrm { Y } = 1 . 0 5 6 \mathrm { X } + 0 . 2 3 9$ , $\mathrm { r } { = } 0 . 9 9 5$ , $_ { \mathrm { N } = 2 1 5 }$ . $\mathrm { Y } =$ Dimension Vista HCYS assay, and $\mathrm { X = }$ BN ProSpec N Latex HCY assay.

A summary of the regression statistics for the different matrices is provided below:

Method Comparison Study   

<table><tr><td rowspan=1 colspan=1>ComparativeMethod/Specimen type</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>CorrelationCoefficient</td></tr><tr><td rowspan=1 colspan=1>HCY on the BNProSpec®/EDTA plasma</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>1.076</td><td rowspan=1 colspan=1>0.350</td><td rowspan=1 colspan=1>0.996</td></tr><tr><td rowspan=1 colspan=1>HCYon the BN ProSpec®/lithiumheparinn plasma</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>1.075</td><td rowspan=1 colspan=1>-0.085</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>HCY on the BNProSpec®/serum</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>1.024</td><td rowspan=1 colspan=1>0.716</td><td rowspan=1 colspan=1>0.996</td></tr></table>

b. Matrix comparison:

Matrix comparison studies were performed by collecting fresh whole blood from a total of 10 donors. Samples were collected into lithium-heparin tube, sodium-heparin tube, EDTA tube, and serum separator tubes. A comparison was performed with matched specimens of serum, EDTA, and lithium and sodium heparin plasma on the Dimension Vista system. Linear regression analysis showed correlations of slopes of 0.9 to 1.10 and $\Gamma \geq 0 . 9 5$ was met when different matrices were compare to the serum sample.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): None

4. Clinical cut-off:

None

5. Expected values/Reference range:

The reference interval is based on a report from the NHANES 1999-2000 study with approximately 7300 participants, which yielded a central $90 \%$ reference range of $3 . 2 -$ $1 0 . 7 \mu \mathrm { m o l / L }$ for vitamin replete adult US males and females.

Literature cited: “Pfeiffer CM et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 2005;82(2):442-450.“

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.